What is Vaxxas?
Headquartered in Brisbane, Australia, Vaxxas is a clinical-stage biotechnology enterprise dedicated to revolutionizing immunization through its HD-MAP technology. By targeting immune cells located just beneath the skin, the platform facilitates superior immune responses with smaller vaccine doses compared to traditional intramuscular injections. The technology is versatile, supporting various modalities including mRNA, protein subunits, and live attenuated vaccines. Beyond clinical efficacy, the HD-MAP system addresses significant logistical hurdles by reducing cold-chain requirements and enabling potential self-administration, positioning Vaxxas as a disruptive force in the multibillion-dollar global vaccine market.
How much funding has Vaxxas raised?
Vaxxas has raised a total of $124.6M across 5 funding rounds:
Series A
$15M
Series B
$20M
Grant
$8.2M
Other Financing Round
$23M
Series D
$58.4M
Series A (2011): $15M, investors not publicly disclosed
Series B (2015): $20M led by OneVentures, Medical Research Commercialisation Fund (MRCF), Healthcare Ventures, and Brandon Capital
Grant (2022): $8.2M supported by Australian Government
Other Financing Round (2022): $23M featuring OneVentures and Uniquest
Series D (2025): $58.4M backed by OneVentures, Brandon Capital, Sprim Global Investments, and LGT Crestone Wealth Management
Key Investors in Vaxxas
OneVentures
OneVentures is a prominent Australian venture capital firm that invests in high-growth technology and healthcare companies, providing both capital and strategic operational support.
Brandon Capital
Brandon Capital Partners specializes in seed and venture capital investments in the biomedical sector, focusing on life science companies that aim to enhance patient outcomes through innovative medical solutions.
Sprim Global Investments
SPRIM Global Investments focuses on investing in companies that enhance R&D capabilities in the life sciences sector, addressing challenges faced by Biotech and Medtech firms throughout clinical development.
What's next for Vaxxas?
With the successful closure of this major strategic investment, Vaxxas is well-positioned to accelerate its lead programs toward commercialization. The company's roadmap focuses on scaling manufacturing capabilities to meet anticipated global demand while continuing to navigate the regulatory landscape for its universal delivery solution. By leveraging its robust clinical data—which includes over 750 participants—Vaxxas aims to solidify its market position as a leader in next-generation medical delivery, ultimately enhancing vaccine accessibility and reducing healthcare costs on a global scale.
See full Vaxxas company page
